This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaluz, S.
Right arrow Articles by Stanbridge, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaluz, S.
Right arrow Articles by Stanbridge, E. J.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, August 2006, p. 5895-5907, Vol. 26, No. 15
0270-7306/06/$08.00+0     doi:10.1128/MCB.00552-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Proteasomal Inhibition Attenuates Transcriptional Activity of Hypoxia-Inducible Factor 1 (HIF-1) via Specific Effect on the HIF-1{alpha} C-Terminal Activation Domain

Stefan Kaluz ,{dagger},{ddagger}* Milota Kaluzová,{dagger},{ddagger} and Eric J. Stanbridge

Department of Microbiology and Molecular Genetics, College of Medicine, University of California at Irvine, Irvine, California 92717

Received 29 March 2006/ Returned for modification 2 May 2006/ Accepted 21 May 2006

The ubiquitin-proteasome pathway (UPP) is involved in regulation of multiple cellular processes. Hypoxia-inducible factor 1{alpha} (HIF-1{alpha}) is a prototypic target of the UPP and, as such, is stabilized under conditions of proteasomal inhibition. Using carbonic anhydrase IX (CAIX) and vascular endothelial growth factor (VEGF) expression as paradigmatic markers of HIF-1 activity, we found that proteasomal inhibitors (PI) abrogated hypoxia-induced CAIX expression in all cell lines tested and VEGF expression in two out of three. Mapping of the inhibitory effect identified the C-terminal activation domain (CAD) of HIF-1{alpha} as the primary target of PI. PI specifically inhibited the HIF-1{alpha} CAD despite activating the HIF-1{alpha} coactivator p300 and another p300 cysteine/histidine-rich domain 1-dependent transcription factor, STAT-2. Coimmunoprecipitation and glutathione S-transferase pull downs indicated that PI does not disrupt interactions between HIF-1{alpha} and p300. Mutational analysis failed to confirm involvement of sites of known or putative posttranslational modifications in regulation of HIF-1{alpha} CAD function by PI. Our data provide evidence for the counterintuitive hypothesis that inhibition of HIF-1 function could be responsible for at least some of the antitumor effects of proteasomal inhibition. Further studies of the mechanism of the PI-induced attenuation of HIF-1{alpha} will provide important, potentially novel insight into regulation of HIF-1 activity and possibly identify new targets for HIF-directed therapy.

* Corresponding author. Mailing address: Department of Microbiology and Molecular Genetics, Medical Science I B210, University of California at Irvine, College of Medicine, Irvine, CA 92697-4025. Phone: (949) 824-5259. Fax: (949) 824-8598. E-mail: skaluz{at}uci.edu.

{dagger} These two authors contributed equally to this work.

{ddagger} Permanent address: Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovak Republic.

Molecular and Cellular Biology, August 2006, p. 5895-5907, Vol. 26, No. 15
0270-7306/06/$08.00+0     doi:10.1128/MCB.00552-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Zhu, K., Chan, W., Heymach, J., Wilkinson, M., McConkey, D. J. (2009). Control of HIF-1{alpha} Expression by eIF2{alpha} Phosphorylation-Mediated Translational Repression. Cancer Res. 69: 1836-1843 [Abstract] [Full Text]  
  • Li, S. H., Shin, D. H., Chun, Y.-S., Lee, M. K., Kim, M.-S., Park, J.-W. (2008). A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Molecular Cancer Therapeutics 7: 3729-3738 [Abstract] [Full Text]  
  • Kaluz, S., Kaluzova, M., Stanbridge, E. J. (2008). Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1. Blood 111: 5258-5259 [Full Text]  
  • Shin, D. H., Chun, Y.-S., Lee, D. S., Huang, L. E., Park, J.-W. (2008). Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111: 3131-3136 [Abstract] [Full Text]  
  • Yu, P., Kodadek, T. (2007). Dynamics of the Hypoxia-inducible Factor-1-Vascular Endothelial Growth Factor Promoter Complex. J. Biol. Chem. 282: 35035-35045 [Abstract] [Full Text]  
  • Birle, D. C., Hedley, D. W. (2007). Suppression of the Hypoxia-Inducible Factor-1 Response in Cervical Carcinoma Xenografts by Proteasome Inhibitors. Cancer Res. 67: 1735-1743 [Abstract] [Full Text]  
  • Papageorgiou, A., Kamat, A., Benedict, W. F., Dinney, C., McConkey, D. J. (2006). Combination therapy with IFN-{alpha} plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Molecular Cancer Therapeutics 5: 3032-3041 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»